Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.
The treatment, Edsivo, aims to treat vascular Ehlers-Danlos syndrome - the most severe type of a hereditary disorder of the connective tissue.
(Reporting by Manojna Maddipatla and Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli) ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692; Reuters Messaging: manojna.kalyani.thomsonreuters.com@reuters.net))
